Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 8/20 | 0.36 |
| ▸ | HTR2C | P28335 | 8/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14956768 | 0.98 | HTR2A (0.35) | HTR2AHTR2CHTR2BADRB1EPHX2 | |
| SCHEMBL27769985 | 0.83 | SSTR4 (0.38) | — | |
| SCHEMBL1991347 | 0.80 | SSTR4 (0.36) | HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL5779163 | 0.79 | SSTR4 (0.35) | HTR2AHTR2C | |
| Trifluoroacetic Acid SCHEMBL31569188 | 0.77 | HRH4 (0.37) | — | |
| SCHEMBL2002227 | 0.73 | HTR2C (0.39) | HTR2AHTR2C | |
| SCHEMBL5779110 | 0.73 | HTR2A (0.39) | HTR2AHTR2C | |
| SCHEMBL24024425 | 0.72 | HTR2A (0.36) | HTR2AHTR2C | |
| SCHEMBL27394528 | 0.72 | HTR2A (0.36) | HTR2AHTR2C | |
| SCHEMBL1776876 | 0.72 | CYP1A2 (0.45) | HTR2AHTR2CHTR2BEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025101780-A1 | PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF | OCTANT, INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| CN-118930551-B | Process for preparing beta-aminopyrazine acetate | 江苏恒瑞医药股份有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-113474346-B | Compositions for inhibiting ubiquitin-specific protease 1 | 福马治疗有限公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-118930551-A | Process for preparing beta-aminopyrazine acetate | 江苏恒瑞医药股份有限公司 | 2024-11-12 | — | — | CN | disclosed |
| US-20220073525-A1 | COMPOSITIONS FOR INHIBITING UBIQUITIN SPECIFIC PROTEASE 1 | FORMA THERAPEUTICS, INC. (US) | 2022-03-10 | — | — | US | disclosed |
| EP-3902802-A1 | COMPOSITIONS FOR INHIBITING UBIQUITIN SPECIFIC PROTEASE 1 | Forma Therapeutics, Inc. (US) | 2021-11-03 | — | — | EP | disclosed |
| WO-2020139988-A1 | COMPOSITIONS FOR INHIBITING UBIQUITIN SPECIFIC PROTEASE 1 | FORMA THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| WO-2020139988-A1 | COMPOSITIONS FOR INHIBITING UBIQUITIN SPECIFIC PROTEASE 1 | FORMA THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| US-20180086765-A1 | NOVEL INTERMEDIATES FOR PREPARING DPP-IV INHIBITORS, PREPARING METHOD THEREOF AND PREPARING METHOD OF DPP-IV INHIBITORS USING THE SAME | KYUNG DONG PHARM. CO., LTD. (KR) | 2018-03-29 | — | — | US | disclosed |
| US-20180086765-A1 | NOVEL INTERMEDIATES FOR PREPARING DPP-IV INHIBITORS, PREPARING METHOD THEREOF AND PREPARING METHOD OF DPP-IV INHIBITORS USING THE SAME | KYUNG DONG PHARM. CO., LTD. (KR) | 2018-03-29 | — | — | US | disclosed |
| US-20120065209-A1 | TETRAHYDRO-IMIDAZO[1,5-a]PYRAZINE DERIVATIVES SALTS, PREPARATION METHODS AND MEDICINAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-03-15 | — | — | US | disclosed |
| US-20120065209-A1 | TETRAHYDRO-IMIDAZO[1,5-a]PYRAZINE DERIVATIVES SALTS, PREPARATION METHODS AND MEDICINAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-03-15 | — | — | US | disclosed |
| US-20120065209-A1 | TETRAHYDRO-IMIDAZO[1,5-a]PYRAZINE DERIVATIVES SALTS, PREPARATION METHODS AND MEDICINAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-03-15 | — | — | US | disclosed |
| WO-2012019427-A1 | PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | 上海恒瑞医药有限公司 (CN) | 2012-02-16 | — | — | WO | disclosed |
| EP-2404921-A1 | SALTS OF TETRAHYDROIMIDAZO Ý1,5-A¨PYRAZINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2012-01-11 | — | — | EP | disclosed |
| US-20100273786-A1 | TETRAHYDRO-IMIDAZ0[1,5-A]PYRAZINE DERIVATIVES, PREPARATION PROCESS AND MEDICINAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2010-10-28 | — | — | US | disclosed |
| US-20100273786-A1 | TETRAHYDRO-IMIDAZ0[1,5-A]PYRAZINE DERIVATIVES, PREPARATION PROCESS AND MEDICINAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2010-10-28 | — | — | US | disclosed |
| US-20100273786-A1 | TETRAHYDRO-IMIDAZ0[1,5-A]PYRAZINE DERIVATIVES, PREPARATION PROCESS AND MEDICINAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2010-10-28 | — | — | US | disclosed |
| EP-2230241-A1 | TETRAHYDRO-IMIDAZOÝ1,5-A¨PYRAZINE DERIVATIVES, PREPARATION METHODS AND MEDICAL USES THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2010-09-22 | — | — | EP | disclosed |
| CN-101641361-A | Tetrahydroimidazo [1, 5-a ] pyrazine derivative, preparation method and application thereof in medicine | SHANGHAI HENGRUI PHARM CO LTD | 2010-02-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086765-A1 | NOVEL INTERMEDIATES FOR PREPARING DPP-IV INHIBITORS, PREPARING METHOD THEREOF AND PREPARING METHOD OF DPP-IV INHIBITORS USING THE SAME | DPP4, DPP7, DPP9 | HTR2A 3996/4885HTR2C 4104/4885HTR2B 3488/4885 |
| US-20220073525-A1 | COMPOSITIONS FOR INHIBITING UBIQUITIN SPECIFIC PROTEASE 1 | USP1, USP2, USP3 | HTR2A 4461/4885HTR2C 4476/4885HTR2B 4647/4885 |
| US-20120065209-A1 | TETRAHYDRO-IMIDAZO[1,5-a]PYRAZINE DERIVATIVES SALTS, PREPARATION METHODS AND MEDICINAL USE THEREOF | DPP4, DPP7, DPP3 | HTR2A 1747/4885HTR2C 855/4885HTR2B 1761/4885 |
| US-20100273786-A1 | TETRAHYDRO-IMIDAZ0[1,5-A]PYRAZINE DERIVATIVES, PREPARATION PROCESS AND MEDICINAL USE THEREOF | DPP4, DPP7, DPP3 | HTR2A 1179/4885HTR2C 892/4885HTR2B 1791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.